Health Canada has approved Puma Biotechnology's Nerlynx, or neratinib, as an extended ancillary treatment for women with early-stage breast cancer who have completed prior adjuvant therapy with Roche's Herceptin, or trastuzumab. Knight Therapeutics, Puma Bio's licensee, will handle the product's commercialization.
Canada OKs Puma Bio's neratinib for early-stage breast cancer
Sign up for FDLI SmartBrief
News for the food and drug law community
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.